Torque, a clinical-stage immuno-oncology company developing Deep-Primed™ T Cell Therapeutics to direct immune power deep within the tumor microenvironment, announced today that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for...
The “Advanced Pharmacovigilance” conference has been added to ResearchAndMarkets.com’s offering. This course will be of maximum benefit to those drug safety professionals who are working both in the clinical and post-marketing safety arena including...
BeiGene Co.,Ltd (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, and SpringWorks Therapeutics Inc., a clinical-stage...
First global telemedicine solution, specifically designed to care for patients in clinical trials. Advancing eCOA with virtual visits, remote clinical care and screening. Globally connected research ecosystem in which every person in the world has the opportunity to...
HPCTC enters a multi-year partnership to establish a database enriched for subjects with NAFLD/NASH as a member of ProSciento’s NASH PASS Site Network HIGH POINT, N.C., June 19, 2019 /PRNewswire/ — High Point Clinical Trials Center, LLC, the largest...
Balixafortide is the most advanced and only CXCR4 antagonist in development in a pivotal Oncology global registration trial. Polyphor today announced the enrollment of the first patient in its FORTRESS clinical trial, the pivotal Phase III study evaluating...
Email
Text